ClinicalTrials.gg

Program

TQC3302

A development code. Also written as “TQC3302 inhalation spray”, “TQC3302 inhalation spray+Tiotropium bromide and olodaterol hydrochloride inhalation spray +Budesonide Powder for Inhalation” and “Tiotropium bromide and olodaterol hydrochloride inhalation spray +Budesonide Powder for Inhalation+ TQC3302 inhalation spray”.

In Sino Biopharmaceutical's pipeline, ICS/LAMA/LABA吸入喷雾剂 (布地奈德/噻托溴铵/奥达特罗吸入喷雾剂). Its studies are mostly in Pulmonary Disease, Chronic Obstructive, led by Sino Biopharmaceutical.

Furthest: phase 1, since Nov 25, 20251 company-led study, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical10 open or runningphase 1since Nov 25, 2025Nov 25, 2025none ahead
  • Named in Sino Biopharmaceutical’s own pipeline as TQC3302, phase 1, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 25, 2025First study: phase 1 study in Pulmonary Disease, Chronic ObstructiveFirst studyNCT07267130 · 33 enrolled · China

TargetBeta

“ICS/LAMA/LABA吸入喷雾剂 (布地奈德/噻托溴铵/奥达特罗吸入喷雾剂)”the company's pipeline, read by Claude · source

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07267130Pulmonary Disease, Chronic Obstructive · China1TerminatedAug 21, 202633

How it is read

Names in the registry

  • “TQC3302 inhalation spray”, 2 entries
  • “TQC3302 inhalation spray+Tiotropium bromide and olodaterol hydrochloride inhalation spray +Budesonide Powder for Inhalation”, 1 entry
  • “Tiotropium bromide and olodaterol hydrochloride inhalation spray +Budesonide Powder for Inhalation+ TQC3302 inhalation spray”, 1 entry
  • “Budesonide Powder for Inhalation+ TQC3302 inhalation spray+ Tiotropium bromide and olodaterol hydrochloride inhalation spray”, 1 entry

Codes read as this program: TQC3302.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.